Kurome Chief Executive Officer and Chief Scientific Officer Jan Rosenbaum, Ph.D. Kurome’s targeted approach has the potential to promise radical advancements in the fight against AML and other forms of cancer, even in settings of adaptive resistance to treatment. Developing more effective cancer treatments with fewer side effects can take years to achieve. When paired with the right leadership, game-changing technology can greatly improve and save lives. Kurome Therapeutics may very well prove to be that life-changing technology in the fight against cancer. That fight is being led by Chief ..read more

Mike Venerable, CincyTech CEO CincyTech-backed education software platform Abre and Miami University partnered to get help to students and faculty with mental wellness resources is another great example of the impact of the Ohio Third Frontier in accelerating the impact of Ohio-based research on the lives of Ohioans. Miami’s Center for School-based Mental Health Programs is led by director Cricket Meehan, Ph.D., which was selected to receive $6 million from the Governor’s Emergency Education Relief fund. In partnership with Abre, Miami University will provide acc ..read more

Are your teams OK? During the past year, all businesses, from life sciences start-ups to established ones, have had to pivot due to external circumstances. Business and industry continue to deal with a global pandemic and — in the United States — social and political unrest. Employees who are parents of school-age children might be trying to figure out how to manage their child’s virtual education while working from home.  Just one of those challenges would be enough to create extraordinary stress on employees, said Chris Powell, founder of CincyTech portfolio company Talme ..read more

Cancer cells are often deceptive in that they’ll continue to adapt and invade the body, making traditional treatments less successful.  These specific types of cells work their way through the body, eventually adapting to chemotherapy and other traditional therapies by developing various resistance mechanisms.  In leukemia, the immune system becomes dysregulated, and signaling pathways used in normal healthy immune cells are co-opted by the cancer cells to help the cancer cells survive these therapies, a process referred to as adaptive resistance. Intercepting these signaling pathway ..read more

Consumers today are bombarded with thousands of digital ads and hundreds of emails each day. NaviStone helps brands break through the noise by converting bits and bytes from the digital world into tangible marketing with ink and paper — customized direct mail postcards. NaviStone is able to model browsing behavior to identify likely customers through retargeting and look-a-like prospecting. The ability to leverage this digital intent data enables brands to provide unique and timely one-to-one customer experiences via direct mail that have proven effective in converting known as well as unknow ..read more

CincyTech today announced that Stacey Barnes, a 7-year-veteran of the organization, has been promoted to Senior Business Operations Manager at the Cincinnati-based venture capital firm. Barnes’ promotion reflects her strong work ethic, integrity and leadership in the organization, said CincyTech Partner Ashley Keating. “Stacey’s role at CincyTech straddles many areas, from leading state compliance reporting to ensuring the seamless operation of our digital infrastructure,” Keating said. “Her contributions make her an invaluable asset.” Prior to joining CincyTech in 2016, Barnes worked at the ..read more

For CincyTech and its portfolio companies, 2022 was bookended by the strong performance that belied that of the national economy. Consider: In January, Enable Injections announced a $215 million Series C financing that has resulted in more local manufacturing jobs and capacity for the maker of Enfuse, a wearable delivery device that replaces IV infusion for at-home use.  In December, the founders of Genetesis – Peeyush Shrivastava, Vineet Erasala and Manny Setegn – were named to the prestigious Forbes “30 under 30” list in healthcare. Earlier in 2022, Genetesis closed $17.5 million in Ser ..read more

Ashley Keating, Partner Over her career at PwC, Ashley acquired a wealth of M&A experience and a multifaceted understanding of the deal and investment processes. For the last six years, she built the infrastructure of CincyTech. We are excited to announce two important changes in the CincyTech team that allow us to continue to drive impact in the region into the future. These changes reflect our focus on building a mission-focused team of investment professionals with deep local ties and a vision to build high growth technology companies that impact the world. First, Ashley Keating will b ..read more

John Rice, Ph.D., CincyTech Managing Director of Life Sciences What are some of the challenges of commercializing biotechnology research? How did the success of pioneering biotech companies like Genentech help change the way we think about the market for biotech, now a multibillion-dollar industry? What venture investors look for before supporting a promising pharmaceutical discovery? Those were among the questions recently addressed during a panel sponsored by the Cleveland-based Harrington Discovery Institute. Cincytech Life Sciences Managing Director John Rice, Ph.D., was among the partici ..read more

Nine CincyTech portfolio clients are finalists for the Fire Awards from Cincy Inno, the Cincinnati Business Courier publication focused on technology in Greater Cincinnati. Winners will be announced in the June 24 print edition of the Business Courier. CincyTech, Lightship Capital and Lightship Foundation were named finalists in the Investor of the Year category. Cincy Inno honors 45 companies throughout the region annually. “As a way to recognize the region’s fastest-growing, most innovative and impactful startups, we're bringing back our annual ‘Fire Awards,’ formally Inno on Fire. It's our ..read more